Physician profile
Francis Dimtri
NPI 1316394935
$20,694.79
in general payments reported to CMS, 2019-2025
28 companies · $5,387 in 2025
The $5,387 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,416 · 2020: $433 · 2021: $1,164 · 2022: $1,601 · 2023: $4,671 · 2024: $6,021 · 2025: $5,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,802 · Food and Beverage: $7,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,802.05 |
| Food and Beverage | $7,278.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $7,781.47 | 2021-2025 | Advisa Dr Mri Surescan, Turbohawk, Micra |
| Boston Scientific Corporation | $3,015.11 | 2020-2025 | Watchman Access System, Watchman Flx, Cds - Mct/Cem Monitoring |
| Abbott Laboratories | $2,749.60 | 2021-2025 | Perclose Proglide, Cardiomems, Supera |
| Cvrx, INC. | $2,261.70 | 2022-2023 | Barostim Neo System |
| Abiomed | $1,672.33 | 2019-2025 | Impella |
| Janssen Pharmaceuticals, INC | $677.38 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $473.89 | 2022-2025 | Camzyos, Eliquis |
| Teleflex LLC | $385.48 | 2019-2025 | Chocolate, Turnpike |
| Novartis Pharmaceuticals Corporation | $349.19 | 2019-2025 | |
| Pfizer INC. | $237.85 | 2022-2024 | |
| Asahi Intecc USA, INC. | $194.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.91 | 2023-2025 | Jardiance |
| Cook Incorporated | $140.85 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.18 | 2023-2025 | Lifevest |
| Amarin Pharma, INC. | $110.07 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $77.24 | 2025 | Verquvo, Capvaxive |
| Kiniksa Pharmaceuticals International, Plc | $42.91 | 2024 | Arcalyst |
| Janssen Scientific Affairs, LLC | $32.39 | 2021 | |
| Alnylam Pharmaceuticals INC. | $31.20 | 2023 | Amvuttra |
| Ekos Corporation | $27.63 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $25.08 | 2024 | |
| Shockwave Medical, INC | $20.92 | 2021 | |
| Medtronic Vascular, INC. | $18.68 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.35 | 2020 | |
| Irhythm Technologies, INC. | $16.06 | 2024 | Zio Xt Patch, Zio Monitor |
| Amgen INC. | $14.18 | 2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $14.11 | 2023 | Farxiga |
| Chiesi USA, INC. | $11.03 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Dimtri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.